

**REMARKS**

Reconsideration is requested.

The Examiner's notation in the Office Action of October 9, 2007 that none of the certified copies of the priority documents have been received is noted. The BIB DATA SHEET similarly indicates that the requirements of 35 U.S.C. § 119 have allegedly not been met. The Examiner is requested to see however the Notice of Acceptance dated September 27, 2005 which confirm receipt by the Patent Office of the priority documents. The Examiner is requested to confirm receipt of the certified copy of the priority document or request a further copy of same from the International Bureau and confirm receipt from the International Bureau.

Claims 5-9 and 17-39, have been canceled, without prejudice. Claims 1-4 and 10-16 have been revised to refer to the elected SEQ ID NO:1835. The recitation of at least 95% finds support, for example, on pages 9-10 of the specification. New claims 40-50 are similar to claims 5-9 and 17-39, respectively, with a reference however to SEQ ID NO:1836, which is the amino acid sequence encoded by SEQ ID NO:1835. Consideration of claims 40-50 with claims 5-9 and 17-39 is requested. No new matter has been added.

The Abstract has been revised above and in the attached in response to the Examiner's objection to the same. No new matter has been added. Withdrawal of the objection is requested.

The Title has been revised above to obviate the objection to the same. Withdrawal of the objection to the Title is requested.

The specification has been revised above to delete the browser-executable code, to obviate the objection to the specification. Withdrawal of the objection is requested.

The claims are believed to define the elected subject matter. Withdrawal of the objection to the claims stated on page 2 of the Office Action dated October 9, 2007 is requested.

The Section 112, second paragraph, rejection of claims 1-4 and 10-16 is obviated by the above amendments. Withdrawal of the rejection is requested.

The Section 112, second paragraph, rejection of claim 13 is obviated by the above amendments. Withdrawal of the rejection is requested.

The Section 112, second paragraph, rejection of claims 1-4, 10-11 and 13 is obviated by the above amendments. Withdrawal of the rejection is requested.

To the extent not obviated by the above amendments, the Section 102 rejection of claims 1-4, 10 and 12-16 over Kim et al (Plant Journal, 2001 February; 25(3):247-59), is traversed. Reconsideration and withdrawal of the rejection are requested in view of the above and the following comments.

The applicants submit that the SCOF-1 protein disclosed in the cited art is only 42% identical to the protein encoded by SEQ ID NO:1835 of the present claims. The claims are submitted to be novel over the cited art which fails to teach each and every aspect of the claimed invention. Withdrawal of the Section 102 rejection is requested.

To the extent not obviated by the above amendments, the Section 102 rejection of claim 11 over Iida (Plant Journal 2000 October; 24(2):191-203), is traversed.

INZÉ et al.  
Appl. No. 10/531,475  
Atty. Ref.: 4982-3  
Amendment  
March 10, 2008

Reconsideration and withdrawal of the rejection are requested in view of the above and the following comments.

The protein encoded by SEQ ID NO: 1835 of the present claims is believed to have only 18% sequence identity with RHL41 of the cited art. The claims are submitted to be novel over the cited art which fails to teach each and every aspect of the claimed invention. Withdrawal of the Section 102 rejection is requested.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned in the event anything further is required in this regard.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:                     /B. J. Sadoff/                      
                    B. J. Sadoff  
                    Reg. No. 36,663

BJS:  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100